We have shown that cellular senescence‐based ultrasound‐targeted imaging could identify reversible senescence early, dynamically monitor and effectively evaluate LAP resistance in HER2+ breast cancer, which has the potential to improve cancer treatment outcomes by altering therapeutic strategies ahead of aggressive recurrences. Here, ERBB2 is linked to breast carcinoma.